CELLECTAR BIOSCIENCES INC

NASDAQ

CLRB

CLRB has a buy rating on Zacks Rank, but it has poor financial. Based on my experience (or lack of) studying the graph, I expect the stock will drop in the future. At the moment the stock is $4.08.

FDA approval this morning MACD curling

Waiting for Phase 2 data to restart the hype for this low floater.

Using fib support/resistance

Tech Analysis

Market Cap. $ 7,625,400

wait for flag breakout

Very interesting to see this stock bottom, breakout, and GAP fill in 1 trading session.

it could go either way but mostly down!

small cloud but in relative strength strong new hot industry see our book on amazon for selecting stockdsin strong groups cmf increasing should pass cloud soon good volume long narrow base